Back

Evaluation of a predictive method for the H&E-based molecular profiling of breast cancer with deep learning

Raharja-Liu, P.; Arslan, S.; Li, X.; Schmidt, J.; Hense, J.; Geraldes, A.; Bass, C.; Brown, K.; Marcia, A.; Dewhirst, T.; Pandya, P.; Singhal, S.; Mehrotra, D.

2022-01-05 cancer biology
10.1101/2022.01.04.474882 bioRxiv
Show abstract

We present a public validation of PANProfiler (ER, PR, HER2), an in-vitro medical device (IVD) that predicts the qualitative status of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) by analysing the hematoxylin and eosin (H&E)-stained tissue scan. In public validation on 648 (ER), 648 (PR) and 560 (HER2) unseen cases with known biomarker status, the device achieves an accuracy of 87% (ER), 83% (PR) and 87% (HER2). The validation offers early evidence of the ability to predict clinically relevant breast biomarkers from an H&E slide in a relevant clinical setting.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.